# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM

# C. Measurand:

# E. Applicant:

Siemens Healthcare Diagnostics Products GmbH

# F. Proprietary and Established Names:

N Latex FLC Kappa assay N Latex FLC Lambda assay N FLC Standard SL N FLC Control SL1 & SL2

# G. Regulatory Information:

1. Regulation section:

21 CFR $\ S$ 866.5550 – Immunoglobulin (light chain specific) immunological test system   
21 CFR $\ S 8 6 2 . 1 6 6 0 - \mathrm { Q }$ uality Control Material (assayed and unassayed)

2. Classification: Class II, test systems

3. Product code:

DFH, Kappa, antigen, antiserum, control DEH, Lambda, antigen, antiserum, control

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended uses:

N Latex FLC Kappa and N Latex FLC Lambda assays

In-vitro diagnostic reagents for the quantitative determination of free light chains (FLC), type kappa or type lambda in human serum and EDTA-plasma by means of particleenhanced immunonephelometry using the BN Systems. FLC measurements are used as an aid in the diagnosis of multiple myeloma (MM) and amyloidosis (AL).

# N FLC Supplementary Reagent

Supplementary reagent for the immunonephelometric determination of free light chains (FLC), type kappa and type lambda on BN Systems. A mixture of both supplementary reagents is used to suppress interference by rheumatoid factors and human anti-mouse antibodies (HAMA).

# N FLC Standard SL

Establishment of reference curves for the determination of free light chains (FLC), type kappa and type lambda on the BN Systems.

N FLC Control SL1 and SL2

The N FLC Controls SL1 and SL2 are for use as assayed accuracy controls and precision controls in the determination of free light chains (FLC), type kappa and type lambda by immunonephelometry with the BN Systems.

2. Indications for use: Same as Intended Uses

3. Special conditions for use statements: For prescription use only

Warning: The result of the FLC Kappa or FLC Lambda in a given specimen determined with assays and or instrument plarformsfromdifferentmanufacturers canvaryduetodifferencesin assaymethodsandreagent specificity.Theresultsreportedbythelaboratorytothephysicianmust includetheidentityof theFLCKappaorFLCLambdaassayused.Valuesobtainedwithdifferent assaymethodscannot be used interchangeably.

4. Special instrument requirements:

BN II (K943997) and BN ProSpec $\textsuperscript { \textregistered }$ Systems (K001647)

# I. Device Description:

The N Latex FLC Kappa and N Latex FLC Lambda assays are comprised of the following reagents in liquid form:

N latex FLC reagents: Consist of suspension of polysterene particles coated with monoclonal antibodies (mouse) to either human FLC Kappa or human FLC Lambda; conjugate of S-adenosyl-cysteine/porcine thyreoglobin $( < 0 . 1 \ \mathrm { g / L } )$ ; conjugate of S-adenosylL-homocysteine hydrolase $( < 1 0 0 \mathrm { U / m L } )$ ; dithiothreitol $( < 0 . 5 \ \mathrm { g / L } )$ . Preservative: Sodium azide $( < 1 \ \mathrm { g / L } )$

N FLC Supplementary Reagents A and B: N FLC Supplementary Reagent A contains mouse immunoglobulin in buffered solution and N FLC Supplementary Reagent B: consist of a buffered salt solution containing detergent. Preservatives in both Supplemntary reagents: Sodium azide $( < 1 \ \mathrm { g / L } )$ .

N FLC Standard SL: Contains human free light chains proteins, human serum albumin and protease inhibitors.

N FLC Controls SL1 and SL2: contains human free light chain proteins, human serum albumin and protease inhibitors.

# J. Substantial Equivalence Information:

1. Predicate device names and 510(k) numbers:

The Binding Site Freelite ® Human Kappa Free Kit for use on the Siemens BN™ II - K031016

The Binding Site Freelite ® Human Lambda Free Kit for use on the Siemens BN™ II - K031016

2. Comparison with predicate:

Kappa and Lambda Reagents:   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceN Latex FLC Kappa NLatex FLC Lambda</td><td rowspan=1 colspan=1>PredicateFreelite® Human KappaFree and Freelite® HumanLambda Free kits on theSiemens BNTMII</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Kappa: Kappa FLCLambda: Lambda FLC</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measurement</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Detection Method</td><td rowspan=1 colspan=1>Nephelometric</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Indication for use</td><td colspan="1" rowspan="1">In-vitro diagnostic reagentsfor the quantitativedetermination of free lightchains (FLC), type kappa ortype lambda, in humanserum and EDTA plasmaby means of particle-enhancedimmunonephelometryusing the BN Systems. FLCmeasurements are used asan aid in the diagnosis ofmultiple myeloma (MM)and amyloidosis (AL).</td><td colspan="1" rowspan="1">This kit is intended for thequantitation of kappa freelight chains or lambda freelight chains in serum andurine on the Siemens BNTMII. Measurement of freelight chains aids in thediagnosis and monitoring ofmultiple myeloma,lymphocytic neoplasms,Waldenstrom'smacroglobulinemia, ALamyloidosis, light chaindeposition disease andconnective tissue diseasessuch as systemic lupuserythematosus in conjunctionwith other laboratory andclinical findings.</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Serum and EDTA plasma</td><td colspan="1" rowspan="1">Serum and urine</td></tr><tr><td colspan="1" rowspan="1">Detection Antibody</td><td colspan="1" rowspan="1">Kappa: Monoclonal mouseanti-human FLC kappaantibody onto polystereneparticlesLambda: Monoclonalmouse anti-human FLClambda antibody ontopolysterene particles</td><td colspan="1" rowspan="1">Kappa: Polyclonal sheepanti-human kappa antibodycoated onto latex particlesLambda: Polyclonal sheepanti-human lambda antibodycoated onto latex particles</td></tr><tr><td colspan="1" rowspan="1">Analytical Measuringranges (Calibrator lotdependent):</td><td colspan="1" rowspan="1">Kappa: 3.4 - 110 mg/LLambda: 1.9 - 60 mg/L</td><td colspan="1" rowspan="1">Kappa: 5.9 - 190 mg/LLambda: 5.0 - 160 mg/L</td></tr><tr><td colspan="1" rowspan="1">Instrument System</td><td colspan="1" rowspan="1">Siemens BN II and BNProSpec Systems</td><td colspan="1" rowspan="1">Siemens BN II</td></tr><tr><td colspan="1" rowspan="1">Reference Interval</td><td colspan="1" rowspan="1">Kappa: 8.24  28.90 mg/LLambda: 9.10  32.60 mg/LRatio: 0.53 - 1.51</td><td colspan="1" rowspan="1">Kappa: 3.30 to 19.40 mg/LLambda: 5.71 to 26.30 mg/LRatio: 0.26 - 1.65</td></tr></table>

Calibrators:   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceN Latex FLC Standard SLfor the BN Systems</td><td rowspan=1 colspan=1>PredicateHuman Kappa FreeStandard and HumanLambda Free Standardon the Siemens BNTMII</td></tr><tr><td rowspan=1 colspan=1>Number of Levels</td><td rowspan=1 colspan=1>One</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reference material</td><td rowspan=1 colspan=1>Internal referencepreparation</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">DeviceN Latex FLC Standard SLfor the BN Systems</td><td colspan="1" rowspan="1">PredicateHuman Kappa FreeStandard and HumanLambda Free Standardon the Siemens BNTMII</td></tr><tr><td colspan="1" rowspan="1">Indication for use</td><td colspan="1" rowspan="1">Establishment of referencecurves for the determinationof free light chains (FLC),type kappa and type lambdaon the BN Systems.</td><td colspan="1" rowspan="1">Used for theestablishment ofreference curves for thedetermination ofFreelite® Kappa andLambda light chains onthe BN II System.</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Consists of a stabilizedliquid containing humanfree light chain proteins,human serum albumin andprotease inhibitors. Contains</td><td colspan="1" rowspan="1">Consists of human serathat contain kappa freelight chain and lambdafree light chainrespectively. They are</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">sodium azide (&lt;1 g/L) as apreservative.</td><td colspan="1" rowspan="1">supplied in a stabilizedliquid form and contain0.099% sodium azide,0.1% E- amino-n-caproicacid (EACA) and 0.01%benzamidine aspreservatives.</td></tr><tr><td colspan="1" rowspan="1">Volume</td><td colspan="1" rowspan="1">3 x 1.0 mL</td><td colspan="1" rowspan="1">2 x 1.0 mL</td></tr><tr><td colspan="1" rowspan="1">Analytical values (Controllot dependent)</td><td colspan="1" rowspan="1">Kappa: 22 mg/LLambda: 32 mg/L</td><td colspan="1" rowspan="1">Kappa: 19.99 mg/LLambda: 16.21 mg/L</td></tr></table>

Controls:   

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">DeviceN FLC Control SL 1N FLC Control SL 2</td><td colspan="1" rowspan="1">PredicateHuman Kappa FreeControl, Human KappaFree High Control,Human Lambda FreeControl and HumanLambda Free HighControl</td></tr><tr><td colspan="1" rowspan="1">Indications for Use</td><td colspan="1" rowspan="1">The N FLC Controls SL1and SL2 are for use asassayed accuracy controlsand precision controls in thedetermination of free lightchains (FLC), type kappaand type lambda byimmunonephelometry withthe BN Systems.</td><td colspan="1" rowspan="1">Used as quality controlsfor the Freelite® Kappaand Lambda assays on theSiemens BN II</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Controls are stabilizedliquids containing humanfree light chain proteins,human serum albumin andprotease inhibitors. Theconcentration of the freelight chains (FLC), typekappa and type lambda is</td><td colspan="1" rowspan="1">Controls consist of humansera that contain kappafree light and lambda freelight chain. They aresupplied in a stabilizedliquid form and contain0.099% sodium azide,0.1% E-amino- n-caproic</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">calibrated against standardpreparations and is lot-dependent. The controlscontain sodium azide (&lt;1g/L) as a preservative.</td><td colspan="1" rowspan="1">acid (EACA) and 0.01%benzamidine aspreservatives.</td></tr><tr><td colspan="1" rowspan="1">Volume</td><td colspan="1" rowspan="1">SL1: 3 vials x 1.0 mLSL2: 3 vials x 1.0 mL</td><td colspan="1" rowspan="1">1 vial x 1.5 mL for eachlevel of control: 2 levelsof Kappa Free controlslevels of Lambda Freecontrols</td></tr><tr><td colspan="1" rowspan="1">Assigned Values (lotdependent)</td><td colspan="1" rowspan="1">Level 1:Kappa: 13 mg/LLambda: 13 mg/LLevel 2:Kappa: 32 mg/LLambda: 32 mg/L</td><td colspan="1" rowspan="1">Human Kappa FreeControl:14.90 mg/LHuman Kappa Free HighControl: 30.10 mg/LHuman Lambda FreeControl:27.7 mg/LHuman Lambda Free HighControl: 55.10 mg/L</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A3 “Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Third Edition”.

CLSI EP6-A “Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline”.

CLSI EP07-A2 “Interference Testing in Clinical Chemistry, Approved Guideline - Second Edition”.

CLSI EP09-A3 “Measurement Procedure Comparison and Bias Estimation using Patient samples, Approved Guideline - third Edition”.

# CLSI EP17-A2 “Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline - Second Edition”

CLSI C28-A3C “Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition”.

# L. Test Principle:

The FLC test systems are based upon the principles of particle-enhanced immunonephelometry. Polystyrene particles coated with monoclonal antibodies to human free light chains, type kappa or lambda, respectively, are agglutinated when mixed with samples containing FLC. These aggregates scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

# M. Performance Characteristics:

1. Analytical performance:

All results met the manufacturer’s pre-determined acceptance criteria.

# a. Precision/Reproducibility:

TheprecisionoftheNLatexFLCKappaandNLatexFLCLambdaFLCassayswereevaluated according to the Clinical and Laboratory Standards Institute (CLSI) EP5-A3 guideline. Serum samples wereobtainedfromcommercialsourcesandsampleswithvaluesclosetonormal, abnormal andveryabnormalanalytelevelswerepooledtoachievetargetconcentrations spanningthe linear range of each FLC assay. Inthe study, the tests were performed onthree levels of serum specimens,andtwolevelsofcontrols.Thesespecimensincludedonesample within $2 5 \%$ of thecutoff/upperlimitofnormalforFLCKappaandFLCLambda.Testingwas performedon three BN II and three BN ProSpec $\textsuperscript { \textregistered }$ instruments with two replicates per run, two runs per day using one lot of the assay-specific reagents. The precision data was analyzed accordingtothree-waynestedANOVAandtheresultsofmean $\mathrm { ( m g / L ) }$ )and $\% C V$ are summarized below:

N Latex FLC Kappa on three BN II Systems   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>11.43</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>1.75</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>1.74</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>2.34</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>3.45</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>25.54</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>2.04</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>3.06</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>81.31</td><td rowspan=1 colspan=1>1.91</td><td rowspan=1 colspan=1>2.35</td><td rowspan=1 colspan=1>1.28</td><td rowspan=1 colspan=1>1.58</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>2.26</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>3.10</td><td rowspan=1 colspan=1>3.81</td></tr><tr><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>14.60</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>2.17</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>3.47</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>4.55</td></tr><tr><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>37.49</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>1.71</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>1.66</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>1.52</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>3.26</td></tr></table>

N Latex FLC Lambda on three BN II Systems   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>10.91</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>1.59</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>4.27</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>5.60</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>27.84</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>1.24</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>1.85</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>1.72</td><td rowspan=1 colspan=1>6.18</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>6.61</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>44.46</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>1.52</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>2.90</td><td rowspan=1 colspan=1>6.52</td><td rowspan=1 colspan=1>3.06</td><td rowspan=1 colspan=1>6.89</td></tr><tr><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>13.83</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>2.09</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>1.44</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>4.07</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>5.07</td></tr><tr><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>37.70</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>2.07</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>1.74</td><td rowspan=1 colspan=1>2.33</td><td rowspan=1 colspan=1>6.18</td><td rowspan=1 colspan=1>2.58</td><td rowspan=1 colspan=1>6.85</td></tr></table>

N Latex FLC Kappa on three BN ProSpec Systems   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>11.03</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>2.47</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>4.56</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>5.24</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>25.05</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>1.21</td><td rowspan=1 colspan=1>4.84</td><td rowspan=1 colspan=1>1.33</td><td rowspan=1 colspan=1>5.32</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>79.04</td><td rowspan=1 colspan=1>1.78</td><td rowspan=1 colspan=1>2.25</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>2.33</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>5.50</td><td rowspan=1 colspan=1>6.96</td><td rowspan=1 colspan=1>6.07</td><td rowspan=1 colspan=1>7.68</td></tr><tr><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>14.19</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>2.78</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>4.03</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>5.22</td></tr><tr><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>36.33</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>1.92</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>2.39</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.69</td><td rowspan=1 colspan=1>4.66</td><td rowspan=1 colspan=1>2.03</td><td rowspan=1 colspan=1>5.58</td></tr></table>

N Latex FLC Lambda on three BN ProSpec Systems   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>10.87</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>2.52</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>4.28</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>27.27</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>2.46</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>2.78</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>3.86</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>44.69</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>2.15</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>1.43</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.76</td><td rowspan=1 colspan=1>3.84</td><td rowspan=1 colspan=1>2.11</td><td rowspan=1 colspan=1>4.17</td></tr><tr><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>13.82</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>1.94</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>3.22</td></tr><tr><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>37.09</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>1.87</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>2.14</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>1.07</td><td rowspan=1 colspan=1>2.87</td></tr></table>

Thelot-to-lot reproducibilityoftheNLatexFLCKappaandNLatexFLCLambdaFLC assayswereevaluated according to the CLSI EP5-A3 guideline. Serum samples wereobtained fromcommercialsourcesandsampleswithvaluesclosetonormal,abnormal andvery abnormalanalytelevelswerepooledtoachievetargetconcentrationsspanningthe linear range of each FLC assay. In the study, the tests were performedon three levels of serum specimens,andtwolevelsofcontrols.Thesespecimensincludedonesamplewithin $2 5 \%$ of thecutoff/upperlimitofnormalforFLCKappaandFLCLambda.Testingwasperformedon oneBN II andoneBNProSpec $\textsuperscript { \textregistered }$ instruments with two replicates per run, two runs per day using three lots of the assay-specific reagents. The resultsof mean $( \mathrm { m g / L } )$ and%CVare summarized below:

Three Lots of N Latex FLC Kappa on one BN II System   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>11.66</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>1.44</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>5.99</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>6.35</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>25.91</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>1.46</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>1.32</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>3.48</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>4.00</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>82.35</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>1.87</td><td rowspan=1 colspan=1>2.27</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>3.52</td><td rowspan=1 colspan=1>4.27</td><td rowspan=1 colspan=1>4.37</td><td rowspan=1 colspan=1>5.31</td></tr><tr><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>14.39</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>4.21</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>4.55</td></tr><tr><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>37.40</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>1.59</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.95</td><td rowspan=1 colspan=1>5.20</td><td rowspan=1 colspan=1>2.09</td><td rowspan=1 colspan=1>5.58</td></tr></table>

Three Lots of N Latex FLC Lambda on one BN II System   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>10.30</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.37</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>8.25</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>8.54</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>26.35</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>5.90</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>6.19</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>41.59</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>1.57</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>3.83</td><td rowspan=1 colspan=1>9.22</td><td rowspan=1 colspan=1>3.93</td><td rowspan=1 colspan=1>9.44</td></tr><tr><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>13.07</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>1.70</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>6.63</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>7.10</td></tr><tr><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>35.13</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>1.93</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>2.06</td><td rowspan=1 colspan=1>5.88</td><td rowspan=1 colspan=1>2.21</td><td rowspan=1 colspan=1>6.30</td></tr></table>

Three Lots of N Latex FLC Kappa on one BN ProSpec System   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>11.18</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>2.92</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>7.20</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>7.87</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>26.15</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>2.29</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>4.55</td><td rowspan=1 colspan=1>1.37</td><td rowspan=1 colspan=1>5.23</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>81.79</td><td rowspan=1 colspan=1>1.94</td><td rowspan=1 colspan=1>2.37</td><td rowspan=1 colspan=1>1.76</td><td rowspan=1 colspan=1>2.15</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>5.44</td><td rowspan=1 colspan=1>6.66</td><td rowspan=1 colspan=1>6.04</td><td rowspan=1 colspan=1>7.39</td></tr><tr><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>14.88</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>3.01</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>6.00</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>7.30</td></tr><tr><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>37.93</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>1.85</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>2.96</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>5.85</td><td rowspan=1 colspan=1>2.58</td><td rowspan=1 colspan=1>6.81</td></tr></table>

Three Lots of N Latex FLC Lambda on one BN ProSpec System   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>10.79</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>3.36</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>0.766</td><td rowspan=1 colspan=1>7.10</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>7.97</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>27.24</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>2.34</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>2.27</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>3.06</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>4.47</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>44.11</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>2.30</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>1.79</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>3.09</td><td rowspan=1 colspan=1>7.01</td><td rowspan=1 colspan=1>3.35</td><td rowspan=1 colspan=1>7.59</td></tr><tr><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>13.89</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>2.90</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>4.67</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>5.76</td></tr><tr><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>37.12</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>1.83</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>3.48</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>2.61</td><td rowspan=1 colspan=1>1.75</td><td rowspan=1 colspan=1>4.72</td></tr></table>

# b. Linearity/assay reportable range:

The studies were performed following the CLSI EP06-A guideline. The linearity of this assay has been demonstrated using test specimens diluted serially in Kappa or Lambda depleted plasma or serum to yield 13 levels within the claimed assay range. Serum and EDTA plasma specimens from healthy donors from a blood bank (one donor each for Kappa EDTA plasma and serum and one donor each for Lambda EDTA plasma and serum) were spiked with purified polyclonal FLC Kappa and FLC Lambda and subsequently diluted with FLC depleted serum or plasma until concentrations of FLC Kappa and FLC Lambda were below the initial measuring range. The diluted samples were measured in three independent measurements. The approximate measuring range of the N Latex FLC Kappa at initial dilution of 1:100 is $3 . 4 { - } 1 1 0 \ \mathrm { m g / L }$ and the approximate measuring range of the N Latex FLC Lambda at initial dilution of 1:20 is $1 . 9 { - } 6 0 \ \mathrm { m g / L }$ .

Tabulated summary of linearity studies:

<table><tr><td rowspan=1 colspan=1>FLCAssay</td><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Sampletype</td><td rowspan=1 colspan=1>RangeTested(mg/L)</td><td rowspan=1 colspan=1>Linearityregressiondata</td><td rowspan=1 colspan=1>95% CI(Slope)</td><td rowspan=1 colspan=1>95% CI(Y-Intercept)</td></tr><tr><td rowspan=1 colspan=1>Kgappah</td><td rowspan=1 colspan=1>BN II</td><td rowspan=1 colspan=1>EDTAPlasma</td><td rowspan=1 colspan=1>1.5-122.0</td><td rowspan=1 colspan=1>Y=1.0176x+0.000</td><td rowspan=1 colspan=1>0.99963—1.03560</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Kappa0S</td><td rowspan=1 colspan=1>BN II</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>1.5-120.0</td><td rowspan=1 colspan=1>Y=1.0120x+0.000</td><td rowspan=1 colspan=1>1.00181—1.02220</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>KappaH</td><td rowspan=1 colspan=1>BNProSpec</td><td rowspan=1 colspan=1>EDTAPlasma</td><td rowspan=1 colspan=1>1.7-139.0</td><td rowspan=1 colspan=1>Y=1.0154x+0.000</td><td rowspan=1 colspan=1>0.99800—1.03274</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Kappa0</td><td rowspan=1 colspan=1>BNProSpec</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>1.5117.0</td><td rowspan=1 colspan=1>Y=0.9872x+0.000</td><td rowspan=1 colspan=1>0.96239—1.01197</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Laimbda00</td><td rowspan=1 colspan=1>BN II</td><td rowspan=1 colspan=1>EDTAPlasma</td><td rowspan=1 colspan=1>1.294.7</td><td rowspan=1 colspan=1>Y=1.0439x+0.000</td><td rowspan=1 colspan=1>1.02283−1.06494</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>LaimbdaE</td><td rowspan=1 colspan=1>BN II</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0.975.1</td><td rowspan=1 colspan=1>Y=1.0528x+0.000</td><td rowspan=1 colspan=1>1.03675−1.06884</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Lambdafe</td><td rowspan=1 colspan=1>BNProSpec</td><td rowspan=1 colspan=1>EDTAPlasma</td><td rowspan=1 colspan=1>0.9-72.2</td><td rowspan=1 colspan=1>Y=1.0451x+0.000</td><td rowspan=1 colspan=1>1.02165−1.06860</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Lambda</td><td rowspan=1 colspan=1>BNProSpec</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0.973.4</td><td rowspan=1 colspan=1>Y=1.0323x+0.000</td><td rowspan=1 colspan=1>1.020881.04381</td><td rowspan=1 colspan=1>N/A</td></tr></table>

High Dose Hook Effect:

No high dose hook effect was observed with FLC Kappa samples up $2 7 , 1 0 0 \mathrm { m g / L }$ or with FLC Lambda samples up to $5 7 { , } 3 0 0 \mathrm { m g / L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability:

In the absence of an international reference standard, the calibration of the assay is traceable to an internally assigned master calibrator.

Stability:

Shelf-life, opened-vial, on-board BN Prospec and on-board BN II studies were performed on the N Latex FLC Kappa and FLC Lambda Reagent, on the N Latex FLC Standard SL, on the N Latex FLC Control SL1 and SL2 and on the N Latex FLC Supplementary Reagent A and B. All results met stability acceptance criteria and the product stability claims are listed in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Shelf Life(unopened)</td><td rowspan=1 colspan=1>Opened</td><td rowspan=1 colspan=1>On-boardBNProSpec</td><td rowspan=1 colspan=1>On-Board BN II</td></tr><tr><td rowspan=1 colspan=1>N Latex FLCKappa Reagent</td><td rowspan=1 colspan=1>18 months</td><td rowspan=1 colspan=1>4 weeks</td><td rowspan=1 colspan=1>2 weeks</td><td rowspan=1 colspan=1>Not stored onboard</td></tr><tr><td rowspan=1 colspan=1>N Latex FLCLambdaReagent</td><td rowspan=1 colspan=1>18 months</td><td rowspan=1 colspan=1>4 weeks</td><td rowspan=1 colspan=1>2 weeks</td><td rowspan=1 colspan=1>Not stored onboard</td></tr><tr><td rowspan=1 colspan=1>N Latex FLCStandard SL</td><td rowspan=1 colspan=1>12 months</td><td rowspan=1 colspan=1>42 days</td><td rowspan=1 colspan=1>Not storedon board</td><td rowspan=1 colspan=1>Not stored onboard</td></tr><tr><td rowspan=1 colspan=1>N Latex FLCControl SL1and SL2</td><td rowspan=1 colspan=1>12 months</td><td rowspan=1 colspan=1>28 days</td><td rowspan=1 colspan=1>14 days</td><td rowspan=1 colspan=1>Not stored onboard</td></tr><tr><td rowspan=1 colspan=1>N Latex FLCSupplementaryReagent A</td><td rowspan=1 colspan=1>18 months</td><td rowspan=2 colspan=1>A/BMixed 4weeks</td><td rowspan=2 colspan=1>A/BMixed 2weeks</td><td rowspan=2 colspan=1>Not stored onboard</td></tr><tr><td rowspan=1 colspan=1>N Latex FLCSupplementaryReagent A</td><td rowspan=1 colspan=1>18 months</td></tr></table>

# d. Detection limit:

Limit of Quantitation (LoQ):

The limit of quantitation(LoQ) for NLatexFLC Kappa and NLatexFLC Lambda was determinedontheBNIIandBNProSpec $\textsuperscript { \textregistered }$ Systems according to theCLSIEP17- A2 guideline.Thelimitofquantitationisthelowestconcentrationofanalytethatcanbe quantitatively determined with stated accuracy.

AllresultsmeasuredonblanksamplesfortheLimitofBlank(LoB)studyyieldedresultsbelow themeasuringrangeforbothassays.SinceLimitofDetection(LoD)iscalculatedusingLoB, theLimitofDetectionisundetermined.

LoQonBNSystems:FLCKappa: $0 . 1 9 5 \mathrm { m g / L }$ andFLCLambda: $0 . 5 3 2 \mathrm { m g / L }$ . The total error was found to be below $1 1 \%$ for both methods.

# e. Analytical specificity:

The N Latex FLC Kappa and FLC Lambda assays were evaluated for interference on BN Systems according to the CLSI EP07-A2 guideline. No interferences were observed with the following tabulated lists of endogenous and exogenous substances with their corresponding concentration labels as shown below:

<table><tr><td colspan="2" rowspan="1">Interference Study</td></tr><tr><td colspan="1" rowspan="1">Interferent (Endogenous andExogenous)</td><td colspan="1" rowspan="1">Concentration level</td></tr><tr><td colspan="1" rowspan="1">RF</td><td colspan="1" rowspan="1">2000 IU/mL</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">10 g/L</td></tr><tr><td colspan="1" rowspan="1">Bilirubin conjugated</td><td colspan="1" rowspan="1">1025 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Bilirubin unconjugated</td><td colspan="1" rowspan="1">618 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Triglycerides</td><td colspan="1" rowspan="1">5 g/L</td></tr><tr><td colspan="1" rowspan="1">Total Protein</td><td colspan="1" rowspan="1">143 g/L</td></tr><tr><td colspan="1" rowspan="1">Amikacin</td><td colspan="1" rowspan="1">136.8 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Acetamidophenol</td><td colspan="1" rowspan="1">1324 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">342 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">308 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">81.6 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">3.62 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Dextran</td><td colspan="1" rowspan="1">60 g/L</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">127 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Ethosuximide</td><td colspan="1" rowspan="1">1770 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">2425μmol/L</td></tr><tr><td colspan="1" rowspan="1">Lidocaine</td><td colspan="1" rowspan="1">51.2 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Penicillin</td><td colspan="1" rowspan="1">161 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">42.9 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">1.4 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Valproic Acid</td><td colspan="1" rowspan="1">3467 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Dexamethasone</td><td colspan="1" rowspan="1">1.53 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Cimetidine</td><td colspan="1" rowspan="1">79.2 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">6.3 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Ethanol</td><td colspan="1" rowspan="1">100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">7.8 nmol/L</td></tr><tr><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">181μmol/L</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">198μmol/L</td></tr><tr><td colspan="1" rowspan="1">Primidone</td><td colspan="1" rowspan="1">183 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">6.2 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">33.3 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">18 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Pentobarbital</td><td colspan="1" rowspan="1">431 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Dextropropoxyphene</td><td colspan="1" rowspan="1">4.91μmol/L</td></tr><tr><td colspan="1" rowspan="1">Heparin Ammonium Salt</td><td colspan="1" rowspan="1">3000 U/L</td></tr><tr><td colspan="1" rowspan="1">Heparin Lithium Salt</td><td colspan="1" rowspan="1">3000 U/L</td></tr><tr><td colspan="1" rowspan="1">Heparin Sodium Salt</td><td colspan="1" rowspan="1">3000 U/L</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">21 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Lithium Chloride</td><td colspan="1" rowspan="1">3.2 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Aminophylline Hydrate(Theophylline)</td><td colspan="1" rowspan="1">222 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Chloramphenicol</td><td colspan="1" rowspan="1">155 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Melphalan</td><td colspan="1" rowspan="1">4000 ng/mL</td></tr></table>

Human Anti-Mouse Antibody (HAMA):

No HAMA interferent was observed in both FLC Kappa and FLC Lambda assays with HAMA samples up to $1 5 . 4 7 \mathrm { m g / L }$ . The Package Insert states: “Nevertheless, complete elimination of this interference from all patient specimens cannot be guaranteed.”

f. Assay cut-off: See expected values/reference range.

2. Comparison studies:

# a. Method comparison with predicate device:

219 samples were tested with the Siemens N Latex FLC Kappa and Lambda assays and the results were compared to the results of the predicate devices. A total of 96 MM and a total of 83 AL serum samples spanning the dynamic range of one or both assays were used in this study. In addition, samples from 24 donors with polyclonal immunoglobulin stimulation and 16 with Chronic Kidney Disease (CKD) were included. 216 of these samples yielded quantitative values in both kappa assays and 218 in both lambda assays.

<table><tr><td rowspan=1 colspan=1>Kit</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>SampleRangeN LatexFLC mg/L</td><td rowspan=1 colspan=1>Slope(PassingBablock)</td><td rowspan=1 colspan=1>95% CI(Slope)</td><td rowspan=1 colspan=1>Y-Intercept(PassingBabloc)</td><td rowspan=1 colspan=1>95% CI(Y-Intercept)</td><td rowspan=1 colspan=1>$R^{2}$</td></tr><tr><td rowspan=1 colspan=1>FLCKappa</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>1.38-13,400</td><td rowspan=1 colspan=1>0.794</td><td rowspan=1 colspan=1>0.742 -0.852</td><td rowspan=1 colspan=1>2.112</td><td rowspan=1 colspan=1>1.134 2.785</td><td rowspan=1 colspan=1>0.889</td></tr><tr><td rowspan=1 colspan=1>FLCLambda</td><td rowspan=1 colspan=1>218</td><td rowspan=1 colspan=1>0.924 -24,300</td><td rowspan=1 colspan=1>1.170</td><td rowspan=1 colspan=1>1.0141.318</td><td rowspan=1 colspan=1>2.163</td><td rowspan=1 colspan=1>0.723 -3.881</td><td rowspan=1 colspan=1>0.950</td></tr></table>

# b. Matrix comparison:

Matrix comparison studies were performed between serum and EDTA plasma on 44 samples. Results are as follows:

<table><tr><td colspan="5">Serum versus EDTA Plasma FLC Kappa Summary</td></tr><tr><td>N=44</td><td>Regression</td><td>Passing Bablock Slope (95% CI)</td><td>PB Intercept (95% CI)</td><td>Median Difference</td></tr><tr><td>Serum vs EDTA</td><td>r= 0.98</td><td>1.014 (0.967  1.036)</td><td>- 0.791 (-1.250 - 0.050)</td><td>-3.5%</td></tr></table>

<table><tr><td colspan="5">Serum versus EDTA Plasma FLC Lambda Summary</td></tr><tr><td>N=44</td><td>Regression</td><td>Passing Bablock Slope (95% CI)</td><td>PB Intercept (95% CI)</td><td>Median Difference</td></tr><tr><td>Serum vs EDTA</td><td>r= 0.99</td><td>1.050 (1.005 - 1.094)</td><td>- 1.10 (-1.91 - -0.19)</td><td>-1.0%</td></tr></table>

3. Clinical studies:

# a. Clinical Sensitivity and specificity:

A total of 342 samples were included in the clinical validation study for the N Latex FLC Kappa and Lambda assay. This validation set included 96 samples from MM patients, 83 samples from AL patients and 163 samples from non-myeloma patients with various clinical conditions: 24 samples from polyclonal immunoglobulin stimulation patients; 16 samples from CKD patients & 123 samples from other

clinical condition patients.

For MM, a total of 259 samples were included in the clinical validation study for the N Latex FLC Kappa and Lambda assay. This validation set included 96 samples from Multiple Myeloma patients, and 163 samples from non-myeloma patients with various clinical conditions.

Clinical sensitivity and specificity summary of the N Latex FLC Kappa and Lambda Ratio for MM are shown in the table below (using the FLC Kappa and Lambda Ratio Reference Interval of 0.53–1.51 as cut-off):   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis of MM</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>N Latex FLCKappa andLambda Ratio</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>158</td><td rowspan=1 colspan=1>162</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>259</td></tr></table>

Clinical Sensitivity: $9 5 . 8 \%$ ( $9 5 \%$ CI: $8 9 . 8 - 9 8 . 4 \%$ Clinical Specificity: $9 6 . 9 \%$ b $9 5 \%$ CI: $9 3 . 0 - 9 8 . 7 \% )$

For AL, a total of 246 samples were included in the clinical validation study for the N Latex FLC Kappa and Lambda assay. This validation set included 83 samples from AL Amyloidosis patients, and 163 non-AL Amyloidosis samples from patients with various clinical conditions.

Clinical sensitivity and specificity summary of the N Latex FLC Kappa and Lambda Ratio for AL are shown in the table below (using the FLC Kappa and Lambda Ratio Reference Interval of 0.53–1.51 as cut-off):

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis of AL</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>N Latex FLCKappa andLambda Ratio</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>74</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>158</td><td rowspan=1 colspan=1>172</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>246</td></tr></table>

Clinical Sensitivity: $8 3 . 1 \%$ ( $9 5 \%$ CI: $7 3 . 7 - 8 9 . 7 \% )$ Clinical Specificity: $9 6 . 9 \%$ $9 5 \%$ CI: $9 3 . 0 - 9 8 . 7 \% )$

$b$ . Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

ReferenceintervalsweredeterminedfromaUS-populationof 201apparentlyhealthy subjects. The reference intervals were calculated nonparametrically and represent the central $9 5 \%$ range of the population.

Thefollowingreferenceintervalsapplyforserumandplasmasamplesfromhealthyadults:   
FLC Kappa: $8 . 2 4 - 2 8 . 9 \mathrm { m g / L }$ b $( 2 . { \dot { 5 } } ^ { \mathrm { t h } } - 9 7 . 5 ^ { \mathrm { t h } }$ percentile)   
FLC Lambda: $9 . 1 0 - 3 2 . 6 \mathrm { m g / L }$ $( 2 . 5 ^ { \mathrm { t h } } - 9 7 . 5 ^ { \mathrm { t h } }$ percentile)   
FLC Kappa/ Lambda Ratio: 0.53 – 1.51 (median $1 . 0 \mathrm { s t } - \mathrm { 9 9 } . 0 ^ { \mathrm { t h } }$ percentile)

The Package Insert states: “Nevertheless,each laboratoryshoulddetermineitsownreference intervalssincevaluesmay vary depending on the individual population studied.”

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.